Teacher Retirement System of Texas Purchases 31,498 Shares of Edwards Lifesciences Co. (NYSE:EW)

Teacher Retirement System of Texas grew its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 780.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,533 shares of the medical research company’s stock after purchasing an additional 31,498 shares during the quarter. Teacher Retirement System of Texas’ holdings in Edwards Lifesciences were worth $2,631,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Advisors Asset Management Inc. grew its position in shares of Edwards Lifesciences by 7.7% during the 3rd quarter. Advisors Asset Management Inc. now owns 11,856 shares of the medical research company’s stock valued at $782,000 after purchasing an additional 852 shares in the last quarter. Larson Financial Group LLC boosted its stake in Edwards Lifesciences by 199.1% during the third quarter. Larson Financial Group LLC now owns 4,391 shares of the medical research company’s stock valued at $290,000 after buying an additional 2,923 shares during the period. Daiwa Securities Group Inc. grew its position in Edwards Lifesciences by 1.5% during the third quarter. Daiwa Securities Group Inc. now owns 90,122 shares of the medical research company’s stock worth $5,947,000 after buying an additional 1,374 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Edwards Lifesciences in the 3rd quarter worth about $825,000. Finally, Truvestments Capital LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at about $109,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the subject of several research analyst reports. The Goldman Sachs Group lifted their target price on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. Truist Financial reiterated a “hold” rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Barclays increased their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price target on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Finally, Wolfe Research lowered Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Trading Down 0.2 %

NYSE EW opened at $71.12 on Thursday. The stock has a market cap of $41.81 billion, a P/E ratio of 10.20, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a 50 day simple moving average of $71.45 and a two-hundred day simple moving average of $70.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Activity

In related news, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at approximately $1,594,475.64. This trade represents a 2.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,553 shares of company stock valued at $4,513,064. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.